Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Rheumatic Disease ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Myofibroblast transcriptome indicates SFRP2(hi) fibroblast progenitors in systemic sclerosis skin.Nat Commun. 2021; 12: 4384
- Fibroblasts and myofibroblasts: their source, function and role in disease.Int J Biochem Cell Biol. 2007; 39: 666-671
- 1 controls fibroblast polarization and tissue fibrosis.Nature. 2019; 566: 344-349
- Skin fibrosis. Identification and isolation of a dermal lineage with intrinsic fibrogenic potential.Science. 2015; 348: aaa2151
- Two succeeding fibroblastic lineages drive dermal development and the transition from regeneration to scarring.Nat Cell Biol. 2018; 20: 422-431
- Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function.Oncogene. 2014; 33: 4767-4777
- Orphan nuclear receptor NR4A1 regulates transforming growth factor-beta signaling and fibrosis.Nature medicine. 2015; 21: 62-70
- The orphan receptor TR3 suppresses intestinal tumorigenesis in mice by downregulating Wnt signalling.Gut. 2012; 61: 714-724
- Vitamin D receptor regulates TGF-beta signalling in systemic sclerosis.Ann Rheum Dis. 2015; 74: e20
- The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor beta and contributes to the development of experimental dermal fibrosis.Arthritis Rheum. 2014; 66: 3140-3150
- Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages.Ann Rheum Dis. 2015; 74: 1317-1324
- Activation of pregnane X receptor inhibits experimental dermal fibrosis.Ann Rheum Dis. 2013; 72: 621-625
- Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis.Ann Rheum Dis. 2012; 71: 785-789
- Nuclear beta-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation.Am J Respir Cell Mol Biol. 2011; 45: 915-922
- Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis.Arthritis Rheum. 2012; 64: 2724-2733
- Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis.Ann Rheum Dis. 2011; 70: 1304-1310
- Wnt/beta-catenin signaling promotes renal interstitial fibrosis.J Am Soc Nephrol. 2009; 20: 765-776
- WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis.J Clin Invest. 2009; 119: 772-787
- Frizzled-7 mediates TGF-beta-induced pulmonary fibrosis by transmitting non-canonical Wnt signaling.Experimental cell research. 2017; 359: 226-234
- Hippo and TGF-beta interplay in the lung field.Am J Physiol Lung Cell Mol Physiol. 2015; 309: L756-L767
- The WNT signaling pathways in wound healing and fibrosis.Matrix Biol : journal of the International Society for Matrix Biology. 2018; 68-69: 67-80
- Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease.Blood. 2021; 137: 2403-2416
- Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis.Ann Rheum Dis. 2017; 77: 626-628
- The transcription factor GLI2 as a downstream mediator of transforming growth factor-β-induced fibroblast activation in SSc.Ann Rheum Dis. 2017; 76: 756-764
- Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy a novel mouse model for scleroderma?.Arthritis Rheum. 2011; 63: 1707-1717
- Functional Wnt signaling is increased in idiopathic pulmonary fibrosis.PLoS One. 2008; 3: e2142
- Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis.Am J Physiol Gastrointest Liver Physiol. 2008; 294: G39-G49
- Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction.Proc Natl Acad Sci U S A. 2010; 107: 21110-21115
- A muscle resident cell population promotes fibrosis in hindlimb skeletal muscles of mdx mice through the Wnt canonical pathway.Am J Physiol Cell Physiol. 2010; 299: C939-C947
- Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis.Nat Commun. 2012; 3: 735
- Beta-catenin mediates mechanically regulated, transforming growth factor-beta 1-induced myofibroblast differentiation of aortic valve interstitial cells.Arterioscler Thromb Vasc Biol. 2011; 31: 590-597
- Upregulation of the Wnt/beta-catenin pathway induced by transforming growth factor-beta in hypertrophic scars and keloids.Acta Derm Venereol. 2006; 86: 300-307
- Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signalling.Ann Rheum Dis. 2017; 76: 773-778
- The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis.Ann Rheum Dis. 2014; 73: 1232-1239
- Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis.Ann Rheum Dis. 2013; 72: 1255-1258
- Beta-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis.Ann Rheum Dis. 2012; 71: 761-767
- Inhibition of glycogen synthase kinase 3 beta induces dermal fibrosis by activation of the canonical Wnt pathway.Ann Rheum Dis. 2011; 70: 2191-2198
- Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis.Science. 2007; 317: 807-810
- Wnt/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells.Arthritis Rheum. 2012; 64: 2734-2745
- Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors.Cancers. 2016; 8: 22
- Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype.Hum Mol Genet. 2014; 23: 2176-2188
- Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis.Arthritis Res Ther. 2009; 11: 220
- Fibrotic extracellular matrix activates a profibrotic positive feedback loop.J Clin Invest. 2014; 124: 1622-1635
- Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis.Cell Death Differ. 2007; 14: 275-285
- Methylation determines fibroblast activation and fibrogenesis in the kidney.Nat Med. 2010; 16: 544-550
- Idiopathic pulmonary fibrosis.Lancet. 2011; 378: 1949-1961
- Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts.Arthritis Rheum. 2006; 54: 2271-2279
- TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN.Nat Cell Biol. 2009; 11 (U263): 881
- MicroRNA mimicry blocks pulmonary fibrosis.EMBO Mol Med. 2014; 6: 1347-1356
- The role of promoter hypermethylation in fibroblast activation and fibrogenesis.J Pathol. 2013; 229: 264-273
- Epigenetic regulation of wound healing and fibrosis.Curr Opin Rheumatol. 2013; 25: 101-107
- Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies.Ann Rheum Dis. 2015 Aug; 74: 1612-1620
- DNA methylation and gene function.Science. 1980; 210: 604-610
- Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex.Nature. 1998; 393: 386-389
- Suppression of SUN2 by DNA methylation is associated with HSCs activation and hepatic fibrosis.Cell Death Dis. 2018; 9: 1021
- Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis.Am J Respir Cell Mol Biol. 2008; 39: 610-618
- Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis.Ann Rheum Dis. 2018; 77: 744-751
- Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.Nat Commun. 2014; 5: 5797
- The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.J Dermatol Sci. 2010; 59: 153-162
- Fli1 represses transcription of the human alpha2(I) collagen gene by recruitment of the HDAC1/p300 complex.PLoS One. 2013; 8: e74930
- Transforming growth factor-beta regulates DNA binding activity of transcription factor fli1 by p300/CREB-binding protein-associated factor-dependent acetylation.J Biol Chem. 2007; 282: 34672-34683
- 5-aza-2'-deoxycytidine inhibits the proliferation of lung fibroblasts in neonatal rats exposed to hyperoxia.Pediatrics and neonatology. 2017; 58: 122-127
- Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis.Arthritis Rheum. 2007; 56: 2755-2764
- TGFβ promotes fibrosis by MYST1-dependent epigenetic regulation of autophagy.Nat Commun. 2021; 12: 4404
- The molecular mechanism of autophagy.Mol Med. 2003; 9: 65-76
- Autophagy intersections with conventional and unconventional secretion in tissue development, remodeling and inflammation.Trends Cell Biol. 2012; 22: 397-406
- Secretory autophagy.Curr Opin Cell Biol. 2015; 35: 106-116
- Atg5 disassociates the V(1)V(0)-ATPase to promote exosome production and tumor metastasis independent of canonical macroautophagy.Dev Cell. 2017; 43 (e717): 716-730
- Role of microRNAs in fibrosis.Open Rheumatol J. 2012; 6: 130-139
- miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis.J Exp Med. 2010; 207: 1589-1597
- MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts.Nature. 2008; 456: 980-U983
- Smad3-mediated upregulation of miR-21 promotes renal fibrosis.J Am Soc Nephrol. 2011; 22: 1668-1681
- MicroRNA-29, a key regulator of collagen expression in systemic sclerosis.Arthritis Rheum. 2010; 62: 1733-1743
- Epigenetic activation and memory at a TGFB2 enhancer in systemic sclerosis.Sci Transl Med. 2019; 11: eaaw0790
- Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis.Ann Rheum Dis. 2021; 80: 1584-1593
- The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics.Int J Mol Sci. 2021; 22: 2719
- An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.Ann Rheum Dis. 2009; 68: 1433-1439
- Translating IL-6 biology into effective treatments.Nat Rev Rheumatol. 2020; 16: 335-345
- Interleukin-6: a new therapeutic target in systemic sclerosis?.Clin Transl Immunology. 2013; 2: e4
- Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis.Ann Rheum Dis. 2012; 71: 1235-1242
- The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review.Clin Exp Rheumatol. 2013; 31: 122-134
- Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.Lancet. 2016; 387: 2630-2640
- Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Respir Med. 2020; 8 (Erratum in: Lancet Respir Med. 2020 Oct;8(10):e75): 963-974
- Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.Ann Rheum Dis. 2018; 77: 1362-1371
- The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets.Arch Dermatol Res. 2020; 312: 81-92
- Role of interleukin-13 in fibrosis, particularly systemic sclerosis.Biofactors. 2013; 39: 593-596
- Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications.Curr Opin Rheumatol. 2021; 33: 463-470
- A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.Ann Rheum Dis. 2020; 79: 1600-1607
- Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis.Rheumatology. 2022; 61: 1948-1956
- Transfer of PBMC from SSc patients induces autoantibodies and systemic inflammation in Rag2-/-/IL2rg-/- mice.Front Immunol. 2021; 12: 677970
- Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial.Lancet Rheumatology. 2021; 3: e489-e497
- Association of defective regulation of autoreactive interleukin-6-producing transitional B lymphocytes with disease in patients with systemic sclerosis.Arthritis Rheum. 2018; 70: 450-461
- Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.N Engl J Med. 2006; 354: 2667-2676
- Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis.Am J Respir Crit Care Med. 2014; 190: 808-817
- Non-invasive biomarkers in pulmonary fibrosis.Respirology. 2009; 14: 788-795
- Functional autoantibodies in systemic sclerosis pathogenesis.Curr Rheumatol Rep. 2015; 17: 34
- Induced antibodies directed to the angiotensin receptor type 1 provoke skin and lung inflammation, dermal fibrosis and act species overarching.Ann Rheum Dis. 2022; 81: 1281-1289
- EUSTAR Rituximab study group. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.Ann Rheum Dis. 2015; 74: 1188-1194
- Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis.Clin Rheumatol. 2021; 40: 3897-3918
- Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial.Arthritis Rheum. 2020; 72: 125-136
- Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.Lancet Rheumatol. 2020; 2: e743-e753
- Oncostatin M stimulates collagen and glycosaminoglycan production by cultured normal dermal fibroblasts: insensitivity of sclerodermal and keloidal fibroblasts.J Invest Dermatol. 1995 Jan; 104: 128-133
- Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis.Rheumatology (Oxford). 2022; 62: 234-242
- Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc?.Rheumatology. 2008; 47: v8-v9
- CTGF mediates Smad-dependent transforming growth factor β signaling to regulate mesenchymal cell proliferation during palate development.Mol Cell Biol. 2013; 33: 3482-3493
- Pamrevlumab, an anti-connective tissuegrowth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.Lancet Respir Med. 2020; 8: 25-33
- Immunolocalization of fibroblast growth factor-1 (FGF-1), its receptor (FGFR-1), and fibroblast-specific protein-1 (FSP-1) in inflammatory renal disease.Kidney Int. 2005; 68: 2621-2628
- S100A4: a common mediator of epithelial-mesenchymal transition, fibrosis and regeneration in diseases?.J Mol Med (Berl). 2008; 86: 507-522
- Extracellular S100A4 as a key player in fibrotic diseases.J Cell Mol Med. 2020; 24: 5973-5983
- S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis.Ann Rheum Dis. 2015; 74: 1748-1755
- The role of type 1 interferon in systemic sclerosis.Front Immunol. 2013; 4: 266
- Whole blood gene expression profiling distinguishes systemic sclerosis-overlap syndromes from other subsets.J Eur Acad Dermatol Venereol. 2020; 34: e236-e238
- Biologics targeting type I interferons in SLE: a meta-analysis and systematic review of randomised controlled trials.Lupus. 2020; 29: 1845-1853
- Targeting interferons as a strategy for systemic sclerosis treatment.Immunol Lett. 2018; 195: 45-54
- Transforming growth factor beta (TGF-β) isoforms in wound healing and fibrosis.Wound Repair Regen. 2016; 24: 215-222
- Targeting TGF-β signal transduction for fibrosis and cancer therapy.Mol Cancer. 2022; 21: 104
- Cat-192 Study Group; Scleroderma Clinical Trials Consortium. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.Arthritis Rheum. 2007; 56: 323-333
- Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.J Clin Invest. 2015; 125: 2795-2807
- PULSAR Trial Investigators. Sotatercept for the treatment of pulmonary arterial hypertension.N Engl J Med. 2021; 384: 1204-1215
Article info
Publication history
Published online: March 01, 2023
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
